他莫昔芬治疗晚期/复发性子宫内膜癌
Tamoxifen therapy in advanced/recurrent endometrial carcinoma.
作者信息
Quinn M A, Campbell J J
机构信息
Gynaecology Unit, Peter MacCallum Cancer Institute, Melbourne, Australia.
出版信息
Gynecol Oncol. 1989 Jan;32(1):1-3. doi: 10.1016/0090-8258(89)90839-1.
PMID:2909443
Abstract
Forty-nine patients with advanced/recurrent endometrial carcinoma were treated with Tamoxifen, 20 mg, twice daily. There were six complete and four partial responses (response rate = 20%). The median survival of responders was 34 months compared to 6 months in nonresponders. Toxicity was minimal.
摘要
49例晚期/复发性子宫内膜癌患者接受了他莫昔芬治疗，剂量为每日2次，每次20毫克。有6例完全缓解和4例部分缓解（缓解率=20%）。缓解者的中位生存期为34个月，而未缓解者为6个月。毒性极小。
Zotero 插件